Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
Teva
Daiichi Sankyo
Chinese Patent Office
Covington
Citi
Cantor Fitzgerald
Queensland Health
Moodys

Generated: October 19, 2017

DrugPatentWatch Database Preview

Otonomy Inc Company Profile

« Back to Dashboard

What is the competitive landscape for OTONOMY INC, and what generic alternatives to OTONOMY INC drugs are available?

OTONOMY INC has one approved drug.

There are four US patents protecting OTONOMY INC drugs.

There are one hundred and twenty-six patent family members on OTONOMY INC drugs in nineteen countries and two supplementary protection certificates in two countries.

Summary for Applicant: Otonomy Inc

International Patents:126
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Otonomy Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,546,363Controlled release corticosteroid compositions and methods for the treatment of otic disorders► Subscribe
9,333,171Controlled-release CNS modulating compositions and methods for the treatment of otic disorders► Subscribe
9,066,855Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders► Subscribe
8,846,770Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders► Subscribe
9,511,020Controlled release corticosteroid compositions and methods for the treatment of otic disorders► Subscribe
8,030,297Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders► Subscribe
8,658,626Controlled release corticosteroid compositions and methods for the treatment of otic disorders► Subscribe
9,603,796Controlled release antimicrobial compositions and methods for the treatment of otic disorders► Subscribe
8,852,626Controlled-release CNS modulating compositions and methods for the treatment of otic disorders► Subscribe
8,680,082Controlled release corticosteroid compositions and methods for the treatment of otic disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Otonomy Inc Drugs

Country Document Number Estimated Expiration
China102099013► Subscribe
Canada2732686► Subscribe
World Intellectual Property Organization (WIPO)2016004231► Subscribe
Argentina072828► Subscribe
Japan5903119► Subscribe
China104940126► Subscribe
Japan2017160232► Subscribe
South Korea20110033295► Subscribe
Israel210720► Subscribe
United Kingdom2459910► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Otonomy Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Dow
Farmers Insurance
Novartis
Deloitte
Argus Health
Fish and Richardson
Julphar
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot